StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)

Close on Nov 18, 2026Market cap $1.18BP/E –Yield –

Nektar Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Nektar Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $55.23M, down 43.9% year over year. For fiscal 2025 it was $55.23M, down 43.9% from the year before. Over ten years it grew -13.3% a year on average. The highest annual figure on record is $1.19B in fiscal 2018.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$55.23M-43.9%
FY2024Dec 31, 2024$98.43M+9.2%
FY2023Dec 31, 2023$90.12M-2.1%
FY2022Dec 31, 2022$92.06M-9.7%
FY2021Dec 31, 2021$101.91M-33.4%
FY2020Dec 31, 2020$152.92M+33.4%
FY2019Dec 31, 2019$114.62M-90.4%
FY2018Dec 31, 2018$1.19B+287.8%
FY2017Dec 31, 2017$307.71M+86.0%
FY2016Dec 31, 2016$165.44M-28.3%
FY2015Dec 31, 2015$230.78M+15.0%
FY2014Dec 31, 2014$200.71M+34.8%
FY2013Dec 31, 2013$148.92M+83.4%
FY2012Dec 31, 2012$81.19M+13.6%
FY2011Dec 31, 2011$71.48M-55.1%
FY2010Dec 31, 2010$159.04M+121.1%
FY2009Dec 31, 2009$71.93M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$21.81M-25.3%
Q3 FY2025Sep 30, 2025$11.79M-51.1%
Q2 FY2025Jun 30, 2025$11.18M-52.4%
Q1 FY2025Mar 31, 2025$10.46M-51.7%
Q4 FY2024Dec 31, 2024$29.18M+22.1%
Q3 FY2024Sep 30, 2024$24.12M-0.1%
Q2 FY2024Jun 30, 2024$23.49M+14.6%
Q1 FY2024Mar 31, 2024$21.64M+0.2%
Q4 FY2023Dec 31, 2023$23.89M+8.5%
Q3 FY2023Sep 30, 2023$24.14M+2.2%
Q2 FY2023Jun 30, 2023$20.50M-5.0%
Q1 FY2023Mar 31, 2023$21.59M-13.0%
Q4 FY2022Dec 31, 2022$22.02M-11.9%
Q3 FY2022Sep 30, 2022$23.63M-5.2%
Q2 FY2022Jun 30, 2022$21.59M-23.8%
Q1 FY2022Mar 31, 2022$24.82M+5.0%
Q4 FY2021Dec 31, 2021$25.01M+6.6%
Q3 FY2021Sep 30, 2021$24.92M-17.0%
Q2 FY2021Jun 30, 2021$28.33M-42.0%
Q1 FY2021Mar 31, 2021$23.65M-53.2%
Q4 FY2020Dec 31, 2020$23.46M-30.7%
Q3 FY2020Sep 30, 2020$30.03M+2.8%
Q2 FY2020Jun 30, 2020$48.85M+109.5%
Q1 FY2020Mar 31, 2020$50.57M+79.2%
Q4 FY2019Dec 31, 2019$33.86M-15.0%
Q3 FY2019Sep 30, 2019$29.22M+5.2%
Q2 FY2019Jun 30, 2019$23.32M-97.9%
Q1 FY2019Mar 31, 2019$28.22M-25.8%
Q4 FY2018Dec 31, 2018$39.83M-58.3%
Q3 FY2018Sep 30, 2018$27.76M-81.8%
Q2 FY2018Jun 30, 2018$1.09B+3044.7%
Q1 FY2018Mar 31, 2018$38.02M+53.7%
Q4 FY2017Dec 31, 2017$95.47M+154.9%
Q3 FY2017Sep 30, 2017$152.93M+320.9%
Q2 FY2017Jun 30, 2017$34.59M+5.6%
Q1 FY2017Mar 31, 2017$24.73M–
Q4 FY2016Dec 31, 2016$37.45M–
Q3 FY2016Sep 30, 2016$36.34M–
Q2 FY2016Jun 30, 2016$32.77M–

More Nektar Therapeutics figures

See a number that looks wrong?